Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | February 19, 2016 | February 23, 2016 |
| STAAR SURGICAL COSTAA · Entity 4851 | Director · President & CEO | January 03, 2025 | January 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 19, 2016 · Filed February 23, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 31,921 |
Reported balance
After 2016-02-19 transaction · row 1
1 source rowRow 1 · 2016-02-19 · Grant · Acquired 19,921 · Balance 31,921 F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 · Expires 2026-02-18 | Direct | 174,657 |
Reported balance
After 2016-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-02-19 · Grant · Acquired 174,657 · Balance 174,657 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 58,219 on 02/19/2017, 58,219 on 02/19/2018, and 58,219 on 02/19/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 58,219 on 02/19/2017, 58,219 on 02/19/2018, and 58,219 on 02/19/2019.
STAAR SURGICAL CO
Report date January 03, 2025 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,519 |
Reported balance
After 2025-01-03 transaction · row 1
1 source rowRow 1 · 2025-01-03 · Tax withholding · Disposed 10,775 · Balance 70,519 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2025 Filed Jan 7, 2025 01:03 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Tax withholdingCommon Stock | 10,775 | $24.54 | $264,418.50 |
DisclosureSEC source: 0000950170-25-002475 · ownership.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,519 Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:20 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 66,627 | $0.00 Strike: $37.64 | $0.00 |
DisclosureSEC source: 0000950170-24-031672 · ownership.xml · derivative · entry 2 FRINZI THOMAS G · CIK 0001663458 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,627 Underlying: Common Stock · 66,627 shares Expires 2034-03-11 F3 · derivative.exercise_date: Stock options granted to the Reporting Person on March 12, 2024. Options will vest and become exercisable as to 1/3 (22,209 shares) on March 12, 2025, with the remaining 2/3 (44,418 shares) vesting and becoming exercisable monthly over the following 24 months in equal amounts on a monthly basis. In the event such amount does not evenly divide into 24 months, the remaining balance of options will vest and become exercisable on March 12, 2027. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:20 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantRestricted Stock Units · Derivative | 74,389 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-031672 · ownership.xml · derivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,389 Underlying: Common Stock · 74,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting. F2 · derivative.exercise_date: RSUs granted to the Reporting Person on March 12, 2024. RSUs will vest as to 1/3 (24,796 shares) on March 12, 2025, 1/3 (24,796 shares) on March 12, 2026, and 1/3 (24,797 shares) on March 12, 2027. F2 · derivative.expiration_date: RSUs granted to the Reporting Person on March 12, 2024. RSUs will vest as to 1/3 (24,796 shares) on March 12, 2025, 1/3 (24,796 shares) on March 12, 2026, and 1/3 (24,797 shares) on March 12, 2027. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 00:14 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Tax withholdingCommon Shares | 10,739 | $29.20 | $313,578.80 |
DisclosureSEC source: 0001209191-24-000551 · doc4.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,294 Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:42 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Tax withholdingCommon Shares | 501 | $52.67 | $26,387.67 |
DisclosureSEC source: 0001209191-23-038173 · doc4.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,033 Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 160,638 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001209191-23-000847 · doc4.xml · derivative · entry 2 FRINZI THOMAS G · CIK 0001663458 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,638 Underlying: Common Stock · 160,638 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options granted become exercisable as follows: 1/3 on 1/3/2024 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 1/3/2026. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Shares | 87,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-000847 · doc4.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Award of 87,805 Restricted Stock Units of Common Stock (RSU), subject to forfeiture rights, which lapse as to 29,268 of the RSUs on 1/3/24, 29,268 of the RSUs on 1/3/25, and 29,269 of the RSUs on 1/3/26. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 22:35 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 2,881 | $0.00 Strike: $62.10 | $0.00 |
DisclosureSEC source: 0001209191-22-038095 · doc4.xml · derivative · entry 3 FRINZI THOMAS G · CIK 0001663458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Underlying: Common Stock · 2,881 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest on the earlier of June 16, 2023 or the Corporation's 2023 Annual Shareholders Meeting, subject to his continued service through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 22:35 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038095 · doc4.xml · nonDerivative · entry 2 FRINZI THOMAS G · CIK 0001663458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The restricted shares vest on the earlier of June 16, 2023 or the Corporation's 2023 Annual Shareholders Meeting, subject to his continued service through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 22:35 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038095 · doc4.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 16, 2022, STAAR Surgical Company's shareholders approved an increase, effective as of June 2021, in the annual equity grants to non-employee directors, which resulted in the award of an additional 355 shares of restricted stock. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 21:55 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043360 · doc4.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,924 F1 · shares: The restrictions on the 807 restricted shares of common stock awarded on his election to the Board of Directors lapse on the earlier of June 24, 2022 or the Corporation's 2022 Annual Meeting, subject to his continued service through that date. Read SEC document |
| July 30, 2020 Filed Aug 4, 2020 20:24 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 2,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044682 · doc4.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,117 F1 · shares: The restrictions on the 2117 restricted shares of common stock awarded on his election to the Board of Directors lapse on the earlier of July 30, 2021 or the Corporation's 2021 Annual Meeting, subject to his continued service through that date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:16 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 971 | $0.00 Strike: $39.73 | $0.00 |
DisclosureSEC source: 0001209191-20-033973 · doc4.xml · derivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971 Underlying: Common Stock · 971 shares Expires 2030-07-29 F1 · derivative.exercise_date: These 971 stock options vest in full on July 30, 2020, subject to Mr. Frinzi's continued service through the vesting date. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 174,657 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019912 · edgar.xml · derivative · entry 2 FRINZI THOMAS G · CIK 0001663458 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,657 Underlying: Common shares · 174,657 shares Expires 2026-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 58,219 on 02/19/2017, 58,219 on 02/19/2018, and 58,219 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019912 · edgar.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,921 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 11, 2016 Filed Jan 13, 2016 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-017729 · edgar.xml · nonDerivative · entry 1 FRINZI THOMAS G · CIK 0001663458 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · shares: These shares represent a retention restricted stock award under the Abbott Laboratories 2009 Incentive Stock Program. The award generally vests on the third anniversary of its grant date and includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.